Chromocell Therapeutics (Chromocell Therapeutics) Change In Payables And Accrued Expense : $1.46 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Change In Payables And Accrued Expense?

Chromocell Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-0.11 Mil. It means Chromocell Therapeutics's Accounts Payable & Accrued Expense declined by $0.11 Mil from Dec. 2023 to Mar. 2024 .

Chromocell Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $2.05 Mil. It means Chromocell Therapeutics's Accounts Payable & Accrued Expense increased by $2.05 Mil from Dec. 2022 to Dec. 2023 .

Chromocell Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Chromocell Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Change In Payables And Accrued Expense Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

-2.97

-0.83

0.64

2.05

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial							0.49	0.29	0.73	0.54	-0.11

Chromocell Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.46 Mil.

Chromocell Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.